| 1 |
Jessica J.Lin, Alice T.Shaw, "Recent Advances in Targeting ROS1 in Lung Cancer", Journal of Thoracic Oncology., Vol. 12, pp. 1611-1625, 2017.
DOI
|
| 2 |
Justin F. Gainor, Alice T. Shaw, "Novel Targets in Non-Small Cell Lung Cancer: and Fusions", , Vol. 18, pp. 865-875, 2013.
|
| 3 |
Robert Roskoski, " ROS1 Protein-Tyrosine Kinase Inhibitors in the Treatment of ros1 Fusion Protein-Driven Non-Small Cell Lung Cancers", Pharmacol Res., Vol.121, pp. 202-212, 2017.
DOI
|
| 4 |
Davare M.A, Vellore N.A, Wagner J.P, Eide C.A, Goodman J.R, Drilon A, Deininger M.W, O'Hare T, Druker B.J, "Structural Insight Into Selectivity and Resistance Profiles of ROS1 Tyrosine Kinase Inhibitors", Proc. Natl. Acad. Sci. pp. 1-10, 215.
|
| 5 |
Rikova K., Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al, "Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer", Cell., Vol. 131, pp.1190-1203, 2007.
DOI
|
| 6 |
Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, Dingemans A.-M.C, Lena H, Monnet I, Rothschild S.I, et al, "Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results from the EUROS1 Cohort", J. Clin. Oncol., Vol. 33, pp.992- 999,2015.
DOI
|
| 7 |
Gainor J.F, Shaw A.T., "Novel Targets in Non-Small Cell Lung Cancer:ROS1 and RET Fusions", Oncologist.,Vol. 18, pp. 865-875, 2013.
DOI
|
| 8 |
McCoach C.E, Le A.T, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies K.D, Merrick D.T, Bunn P.A, et al, "Resistance Mechanisms to Targeted Therapies in ROS1p and ALKp Non-Small Cell Lung Cancer", Clin Cancer Res., Vol. 24, pp . 3334-3347,2018.
DOI
|
| 9 |
Drilon A, Somwar R, Wagner J.P, Vellore N.A, Eide C.A, Zabriskie M.S, Arcila M.E, Hechtman J.F, Wang L, Smith R.S, et al, "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-R earranged Lung Cancer", Clin. Cancer Res., Vol. 22, pp. 2351-2358, 2016.
DOI
|
| 10 |
Bergethon K, Shaw A.T, Ou S.-H.I, Katayama R, Lovly C.M, McDonald N.T, Massion P.P, Siwak-Tapp C, Gonzalez A, Fang R, et al, "ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers", J. Clin. Oncol., Vol. 30, pp. 863-870, 2012.
DOI
|
| 11 |
Dallakyan, S. and Olson, A.J, "Small-molecule library screening by docking with PyRx", In Chemical biology., pp. 243-250, 2015.
|
| 12 |
Leach, A. R, Shoichet, B. K, &Peishoff, C. E, "Prediction of protein- ligand interactions. Docking and scoring: successes and gaps", Journal of medicinal chemistry., Vol. 49, pp. 5851-5855, 2006.
DOI
|
| 13 |
Trott, O, & Olson, A. J. "AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading", Journal of computational chemistry., Vol. 3 ,pp. 455-461, 2010.
|
| 14 |
Parr RG, Yang W, "Density-functional theory of atoms and molecules", Oxford University Press, New York, 1989.
|
| 15 |
Fukui, K., "The role of frontier orbitals in chemical reactions", (Nobel Lecture). AngewandteChemie International Edition in English, Vol. 21 pp. 801-809,1982.
DOI
|
| 16 |
Chattaraj, P.K. and Roy, D.R, "Update 1 of: electrophilicity index", Chemical reviews., Vol. 107, pp. 46-74,2007.
|
| 17 |
Chattaraj, P.K, Maiti, B. and Sarkar, U,"Philicity: a unified treatment of chemical reactivity and selectivity", The Journal of Physical Chemistry A, Vol. 107, pp. 4973-4975, 2003.
DOI
|
| 18 |
Alice T. Shaw, Sai-Hong I. Ou, YungJue Bang, D. Ross Camidge, et al, "Crizotinib in ROSl-Rearranged NonSmall-Cell Lung Cancer", Vol. 371, pp. 1963-1971, 2014.
|
| 19 |
Chattaraj, P.K, Sarkar, U, Roy, D.R, Elango, M., Parthasarathi, R. and Subramanian, V, "Is electrophilicity a kinetic or a thermodynamic concept?", Vol 45A, pp. 1099-1112, 2006.
|
| 20 |
Pires, D. E., Blundell, T. L., &Ascher, D. B., "pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures", Journal of medicinal chemistry., Vol. 58, pp. 4066-4072, 2015.
DOI
|
webmaster
